CN100423738C - Chinese medicine preparation for treating cardio-cerebral vascular disease and its preparing method - Google Patents
Chinese medicine preparation for treating cardio-cerebral vascular disease and its preparing method Download PDFInfo
- Publication number
- CN100423738C CN100423738C CNB2004100715424A CN200410071542A CN100423738C CN 100423738 C CN100423738 C CN 100423738C CN B2004100715424 A CNB2004100715424 A CN B2004100715424A CN 200410071542 A CN200410071542 A CN 200410071542A CN 100423738 C CN100423738 C CN 100423738C
- Authority
- CN
- China
- Prior art keywords
- ethanol
- flos carthami
- extract
- radix ginseng
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 title abstract description 48
- 238000000034 method Methods 0.000 title description 14
- 208000019553 vascular disease Diseases 0.000 title 1
- 241000208340 Araliaceae Species 0.000 claims abstract description 61
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 61
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 61
- 235000008434 ginseng Nutrition 0.000 claims abstract description 61
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 175
- 239000000843 powder Substances 0.000 claims description 51
- 241000628997 Flos Species 0.000 claims description 50
- 239000009636 Huang Qi Substances 0.000 claims description 44
- 239000000284 extract Substances 0.000 claims description 44
- 238000011282 treatment Methods 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 22
- 239000008215 water for injection Substances 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 9
- 238000005325 percolation Methods 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 230000000274 adsorptive effect Effects 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 19
- 210000004369 blood Anatomy 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 14
- 230000017531 blood circulation Effects 0.000 abstract description 12
- 206010008118 cerebral infarction Diseases 0.000 abstract description 8
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 6
- 210000004351 coronary vessel Anatomy 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 5
- 230000036772 blood pressure Effects 0.000 abstract description 4
- 208000029078 coronary artery disease Diseases 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 230000004089 microcirculation Effects 0.000 abstract description 4
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000002792 vascular Effects 0.000 abstract description 3
- 201000006474 Brain Ischemia Diseases 0.000 abstract description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 2
- 206010020772 Hypertension Diseases 0.000 abstract description 2
- 239000002671 adjuvant Substances 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract description 2
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 2
- 230000035939 shock Effects 0.000 abstract description 2
- 244000020518 Carthamus tinctorius Species 0.000 abstract 4
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 4
- 229940107666 astragalus root Drugs 0.000 abstract 4
- 230000004913 activation Effects 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000004530 effect on cardiovascular disease Effects 0.000 abstract 1
- 230000004217 heart function Effects 0.000 abstract 1
- 210000000777 hematopoietic system Anatomy 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 19
- 239000006187 pill Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 235000020710 ginseng extract Nutrition 0.000 description 8
- 235000006533 astragalus Nutrition 0.000 description 7
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 6
- 241001061264 Astragalus Species 0.000 description 5
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 description 5
- 206010019280 Heart failures Diseases 0.000 description 5
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 229960002275 pentobarbital sodium Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- 229940008099 dimethicone Drugs 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 150000002333 glycines Chemical class 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000009760 functional impairment Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000002254 renal artery Anatomy 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 2
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- -1 extractum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000004552 Lacunar Stroke Diseases 0.000 description 1
- 206010051078 Lacunar infarction Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- 229940085034 digoxin 0.25 mg Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000009333 weeding Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a traditional Chinese medicine preparation for curing cardiovascular diseases and cerebrovascular diseases and a preparation method of the traditional Chinese medicine preparation. The traditional Chinese medicine preparation is prepared by the step: one kind of ginseng, astragalus root and safflower or the combination of two kinds of the ginseng, the astragalus root and the safflower is matched with proper adjuvant materials for being prepared into a preparation accepted by medicine. Compared with the prior art, the ginseng in the traditional Chinese medicine preparation can resist shock, regulate heart functions and enhance organism immunity functions; the astragalus root in the traditional Chinese medicine preparation can strengthen the hearts, reduce blood pressure, reduce vascular resistance, promote the hematopoietic systems, and enhance the organism immunity functions; the safflower can expand the coronary arteries, increase coronary artery blood flow, improve microcirculation, reduce blood fat and blood pressure, etc. When the ginseng, the astragalus root and the safflower are mixed for use, the effects of qi benefit, blood circulation activation, qi flourish, blood activation, stale removal and freshness formation are realized. The preparation provided by the present invention has a favorable curative effect on cardiovascular diseases and cerebrovascular diseases, such as coronary diseases, stenocardia, myocardial ischemia, cerebral ischemia, cerebral infarction, high blood pressure, etc.
Description
Technical field:
The present invention relates to treat the Chinese medicine preparation and the preparation method of the heart, cerebrovascular disease, belong to technical field of Chinese medicine.
Technical background: along with social senilization and growth in the living standard, the sickness rate and the case fatality rate of cardiovascular and cerebrovascular disease rise day by day.Studies show that according to nearest one, comprise that in 8 major areas, the whole world investigation of both developed and developing country shows that ischemic heart desease and cerebrovascular disease have become the main cause of death.In addition, also have a large amount of cardiovascular and cerebrovascular disease patients to become the important crowd who needs medical care.Not only medical expense is huge, because of the loss that disabled and disablement cause can not be estimated especially.Although the diagnosis and treatment means are showing improvement or progress day by day at present, cardiovascular and cerebrovascular disease is still the difficult problem that the world today is difficult to overcome.Therefore the pure traditional Chinese compound medicine of inventing little, the cheap treatment cardiovascular and cerebrovascular disease of a kind of determined curative effect, safe ready, side effect seems especially important.
Summary of the invention:
The objective of the invention is to disclose a kind of Chinese medicine preparation that is used for the treatment of the heart, cerebrovascular disease and preparation method thereof.The present invention constitutes like this: Radix Ginseng 10-2000 part, X 20-5000 part.X is one or both combinations in the Radix Astragali, the Flos Carthami, is equipped with suitable adjuvant again and makes acceptable preparation.Described preparation comprises: injection, freeze-dried powder, capsule, soft capsule, tablet, granule, pill, microcapsule, micropill, concentrated pill, drop pill, slow releasing preparation, controlled release preparation, quick releasing formulation, targeting preparation, oral liquid, syrup, powder, mixture, powder, spray, medicated wine, tincture, lozenge, extractum, fluid extract.
The present invention is directed to prior art, extract the Radix Astragali and Radix Ginseng, being chosen as of its extraction process with ethanol reflux extraction:
| Extracting method | Astragaloside content | The ginsenoside | The panoxadiol |
| Ethanol reflux extraction | 0.102％ | 2.16％ | 1.315％ |
| Decoction and alcohol sedimentation technique | 0.077％ | 0.76％ | 0.593％ |
| Percolation | 0.052％ | 1.81％ | 1.039％ |
According to the water-soluble characteristics of important effective ingredient carthamin in the Flos Carthami, adopt the decocting cooking method to extract Flos Carthami, the selection result of the test of its extraction process condition is:
| Decocting time | Decoct number of times | Amount of water | Carthamin content |
| 2 hours | 1 | 10 times of amounts | 18.65％ |
| 2 hours | 2 | 10 times of amounts | 20.08％ |
| 2 hours | 3 | 10 times of amounts | 24.58％ |
In experiment, find in addition, Radix Ginseng, the Radix Astragali are pulverized carefully more, bioavailability in its decoction process is high more, if but the medical material granularity too greatly then easily be difficult in the pasty state leaching in large-scale production process, thereby influence the quality of medicine, find that through experiment contrast back under the existing equipment situation, it is best that Radix Ginseng, astragalus membranaceus powder are broken into the drug quality of coarse powder.With the Flos Carthami extract precipitate with ethanol, can effectively remove the impurity such as tannin in the medicinal liquid, the active constituent content in the medicine is increased, reduce untoward reaction due to the impurity in the medicinal liquid simultaneously, increase the curative effect of medicine.
The present invention can participate in Radix Astragali prescription by the people, and its prescription is: Radix Ginseng 10-2000 part, Radix Astragali 20-5000 part.Its preparation technology is: get Radix Ginseng, be ground into the above fine powder of 80 orders, get the Radix Ginseng powder.Other gets the Radix Astragali, and the water decocting method extracts, once reach once with the ethanol precipitate with ethanol more than, contain the alcohol amount for the first time and be 50-75%, secondary and secondary are later contains alcohol and measures and be 70%-99.9%.Reclaim ethanol and be condensed into extractum, drying promptly gets Radix Astragali extract.With Radix Ginseng powder, Radix Astragali extract mix homogeneously, can make different products according to conventional method again.
The present invention also can participate in the Flos Carthami prescription by the people, and its prescription is: Radix Ginseng 10-2000 part, Flos Carthami 20-5000 part.Its preparation technology is: get the ginseng crude drug and be ground into coarse powder, make solvent with 45-80% ethanol, soaked 3-15 days, carry out percolation, add the ethanol that 15-40 doubly measures altogether, merge percolate, reclaim ethanol and be condensed into extractum, drying promptly gets Radix Ginseng extract.Other gets Flos Carthami powder and is broken into the above fine powder of 60 orders, with Flos Carthami powder, Radix Ginseng extract mix homogeneously, can make different products according to conventional method again.
The present invention can be by Radix Ginseng, Radix Astragali and Flos Carthami prescription, and its prescription is: Radix Ginseng 10-2000 part, Radix Astragali 10-3000 part, Flos Carthami 10-2000.Its preparation technology is: get Radix Ginseng, astragalus membranaceus powder is broken into coarse powder, uses alcohol reflux, reclaim ethanol and also be condensed into extractum, Radix Ginseng, Radix Astragali extract.Other gets Flos Carthami, decocts with water, and filters, and merging filtrate more than adding ethanol precipitate with ethanol once reaches once, contains the alcohol amount for the first time and is 50-75%, and the alcohol amount that contains more than secondary and the secondary is 70-99%.Leave standstill, filter, reclaim ethanol, get Flos Carthami extract.With Radix Ginseng, Radix Astragali extract and Flos Carthami extract mix homogeneously, can make different products according to conventional method again.。
The technology that the present invention makes injection is:
Get Radix Ginseng, the Milkvetch Root pulverize separately becomes coarse powder, uses alcohol reflux, reclaim ethanol and also be condensed into extractum, Radix Ginseng, Radix Astragali extract.Other gets Flos Carthami, decocts with water, and filters, and merging filtrate more than adding ethanol precipitate with ethanol once reaches once, contains the alcohol amount for the first time and is 50-75%, and the alcohol amount that contains more than secondary and the secondary is 70-99%.Leave standstill, filter, reclaim ethanol, get Flos Carthami extract.With the glucose mix homogeneously of Radix Ginseng, Radix Astragali extract, Flos Carthami extract and 1-50%, add in an amount of water for injection and dissolve, and continue to add and add to the full amount of water for injection, transfer pH value 2-7, filter, embedding, promptly get ejection preparation.
Because this Chinese medicine injection is hypisotonic solution, intravenous injection can produce human body during to human body to stimulate, but also can influence the absorption of medicine, so we can add osmotic pressure regulator when making intravenous fluid.
| Osmotic pressure regulator | Consumption | Effect |
| Glucose | 5％ | Pharmacological evaluation has no adverse reaction; Also not having precipitation in the storage process produces |
| Sodium chloride | 5％ | Pharmacological evaluation has no adverse reaction; But there is small amount of precipitate to produce in the storage process |
| Mannitol | 5％ | The nothing precipitation produces but influences the absorption of human body to medicine |
| Sorbitol | 5％ | Do not have precipitation and produce, but diuresis is arranged, influence the absorption of human body medicine |
| Xylitol | 5％ | The nothing precipitation produces but in the pharmacological evaluation mouse kidney is had infringement |
The technology that the present invention makes freeze-dried powder injection is:
Get Radix Ginseng, the Milkvetch Root pulverize separately becomes coarse powder, makes solvent with 45-80% ethanol, soaks 3-15 days, carries out percolation, adds the ethanol that 15-40 doubly measures altogether, merges percolate, reclaims ethanol and also is condensed into extractum, drying promptly gets Radix Ginseng, Radix Astragali extract.Other gets Flos Carthami, decocts with water, and filters, and filtrate is crossed macroporous adsorptive resins, uses ethanol elution, collects eluent and concentrating under reduced pressure and becomes extractum, gets Flos Carthami extract.With the lactose mix homogeneously of Radix Ginseng, Radix Astragali extract, Flos Carthami extract and 1-50%, add in an amount of water for injection and dissolve, and continue to add and add to the full amount of water for injection, transfer pH value 2-7, ultrafiltration, fill, lyophilization promptly gets freeze-dried products.
Because the outward appearance after the herb liquid lyophilization of the present invention is bad, so add excipient in medicinal liquid.
| Excipient | Consumption | Appearance character |
| Glucose | 15％ | Big gun and volumetric expansion phenomenon have been arranged |
| Trehalose | 15％ | Volume-diminished, irregular colour is even |
| Lactose | 15％ | Constancy of volume, color even, outward appearance is better |
| Glycine | 15％ | Irregular colour is even, and lamination is arranged |
The technology that the present invention makes drop pill is: get the ginseng crude drug and be ground into coarse powder, make solvent with 45-80% ethanol, soaked 3-15 days, carry out percolation, add the ethanol that 15-40 doubly measures altogether, merge percolate, reclaim ethanol and be condensed into extractum, drying promptly gets Radix Ginseng extract.Other gets Flos Carthami powder and is broken into the above fine powder of 60 orders, and with Flos Carthami powder, Radix Ginseng extract mix homogeneously, the PEG400 that medicated powder 0.1-10 is doubly measured adds mix homogeneously in the above drug powder, splashes in the dimethicone and cools off, and promptly gets drop pill.
| Substrate | Medicine and substrate ratio | Condensing agent | Fusion mode, shaping situation and sedimentation situation | The molten diffusing time |
| Glycerol | 1: 1 | Liquid paraffin | Be difficult for mixing, the toughness material is separated out, and sedimentation velocity is fast, and ball shape is flat, and roundness is bad. | 18min |
| Glycerol | 1: 2 | Oleum Glycines | The energy mixing, sedimentation velocity is moderate, and ball shape rounding is non-caked. | 25min |
| Glycerol | 1: 3 | Dimethicone | The energy mixing, sedimentation velocity is fast slightly, and ball shape is rounding not, not molding. | 19min |
| PEG400 | 1: 1 | Liquid paraffin | The energy mix homogeneously, sedimentation velocity is moderate, and ball shape is better, and bonding keeps up with. | 30min |
| PEG400 | 1: 2 | Oleum Glycines | Easy mix homogeneously, sedimentation velocity is moderate, and ball shape rounding is non-caked. | 29min |
| PEG400 | 1: 3 | Dimethicone | Easy mix homogeneously, formability is good, the smooth surface densification, rounding, non-caked. | 24min |
The technology that the present invention makes capsule is:
Get Radix Ginseng, be ground into the above fine powder of 80 orders, get the Radix Ginseng powder.Other gets the Radix Astragali, and the water decocting method extracts, and merging filtrate also is condensed into extractum, once reach once with the ethanol precipitate with ethanol more than, contain the alcohol amount for the first time and be 50-75%, secondary and secondary are later contains alcohol and measures and be 70%-99.9%.Reclaim ethanol and be condensed into extractum, drying promptly gets Radix Astragali extract.With the Pulvis Talci mix homogeneously of Radix Ginseng powder, Radix Astragali extract and 0.1-5%, use alcohol granulation, filling promptly gets capsule.
Since invention when making capsule flowability bad, simple filler not is so can add fluidizer.
| Fluidizer | Consumption | Filling effect |
| Pulvis Talci | 1％ | Simple filler, its content uniformity is better, and more stable |
| Calcium stearate | 1％ | Simple filler, but its content uniformity is wayward |
| Hard paraffin | 1％ | Medicine content uniformity instability |
In more than forming, every part of representative be weight portion. weight is calculated with crude drug, if be unit with the gram, more than form and can be made into 1000 doses of pharmaceutical preparatioies, described 1000 doses of fingers, the final drug preparation of making, as make injection 1000ml, 1000 of soft capsules, 1000 of drop pill, 1000 of capsules, 1000 in tablet, oral liquid 1000ml etc. can make 100-1000 as freeze-dried powder to prop up, and can make the 50-500 bag as granule.More than form,, can be made into the preparation of 50-1000 taking dose if be unit with the gram, but every day 1-5 time, each 1-20 agent, as 1-20 prop up, bottle, bag, or sheet, determine usage and dosage according to patient's situation in use.
Compared with prior art, the present invention is made up of Radix Ginseng, Radix Astragali and Flos Carthami, and wherein Radix Ginseng has the effect of strongly invigorating primordial QI, tonifying the lung strengthening the spleen, energy shock, adjusting heart body and enhancing body's immunological function; The effect of Radix Astragali tool invigorating QI to consolidate the body surface resistance diuretic, nourishing blood and promoting granulation poison holding.The effect of energy heart tonifying, blood pressure lowering, reduction vascular resistance, promotion hemopoietic system and enhancing human body immunity function; Flos Carthami has the function of blood circulation promoting and blood stasis dispelling, energy coronary artery dilator, coronary blood flow increasing, microcirculation improvement, blood fat reducing, blood pressure lowering etc.All medicines share, QI invigorating with invigorate blood circulation and usefulness, the prosperous blood of gas is capable, the blood circulation of qi promoting is also prosperous, plays benefiting QI for activating blood circulation altogether, the effect of weeding out the old and bring forth the new.Preparation provided by the invention has good curative effect for treating cardiovascular and cerebrovascular disease such as coronary heart disease, angina pectoris, myocardial ischemia, cerebral ischemia, cerebral infarction, hypertension etc.
In order to verify curative effect of the present invention, the spy has carried out following effect experiment:
One, drop pill of the present invention is to the influence of experimental heart failure domesticated dog arteria coronaria renal blood flow
1 material and method:
1.1 experiment material:
1.1.1 animal: 20 of healthy adult hybrid dogs, body weight 12.28 ± 0.69kg, male and female dual-purpose.
1.1.2 medicine: drop pill of the present invention; Pentobarbital sodium; Digoxin 0.25mg/ sheet; Heparin sodium injection; 0.9% sodium chloride injection.Above-mentioned experiment medicine all is mixed with equal-volume 3ml/kg with normal saline before experiment except that pentobarbital sodium, heparin, through duodenal administration.
1.2 experiment grouping: laboratory animal is divided into four groups at random, 5 every group.A group: be the blank group, raise in the experiment with normal saline 3ml/kg; B group: low dose group of the present invention, 5g crude drug/kg; C group: high dose group of the present invention, 10g crude drug/kg; D group: positive controls, digoxin 100 μ g/kg.
1.3 experimental technique: laboratory animal pentobarbital sodium 30mg/kg intravenous anesthesia, tracheal intubation connects the phrenoton and separates right lateral thigh Jing Mai ﹠amp; Connect the constant speed peristaltic pump, in order to the input pentobarbital sodium; Separate right common femoral artery, intubate is measured arteriotony BP; Left side the 4th intercostal is opened breast, exposes heart, cuts off pericardium, makees the pericardium bed, separates LCA and aorta, places the electromagnetic flowmeter probe respectively, measures coronary flow CBF and cardiac output CO.Abdominal operation separates renal artery and places the electromagnetic flowmeter probe, measures renal artery blood flow amount KBF.Above-mentioned every index synchronous recording is in polygraph.
Execute abdominal operation, duodenal intubation is in order to giving institute's reagent thing.Intravenous injection heparin injection 125U/kg carries out heparinization, after 30 minutes, writes down every index, as basic value before the drop pill of the present invention.Import 2% pentobarbital sodium through the peristaltic pump constant speed, input quantity is 0.2ml/minkg.Change maximum rate with left ventricular pressure and descend 70% as the heart failure index, reaching this value back, to adjust the pentobarbital sodium amount of feeding be 0.08ml/minkg, continues 15 minutes, makes left ventricular end diastolic presssure keep stable, writes down index behind every heart failure, is worth before the medicine.Duodenum feeds institute's reagent thing.Respectively at writing down every observation index behind the medicine in 10,20,30,45,60,90,120,180 minutes.
1.4 statistical method adopts t check and X
2Check.
2, result: two dosage groups of drop pill of the present invention have the effect of increase CBF in various degree, behind the medicine 90 minutes, 10g crude drug/kg dosage group CBF 21.80 ± 7.66ml/min before the medicine increases to 37.60 ± 15.53ml/min, increase by 71.16% ± 18.28%, with before the medicine relatively P＜0.05 and with matched group relatively all there were significant differences in P＜0.01.
Two dosage groups of drop pill of the present invention are not remarkable to CO influence. two dosage groups all can obviously increase KBF, and relatively reach before the medicine and matched group more all there were significant differences P＜0.05～0.01.
3, discuss: originally studies confirm that, drop pill of the present invention can improve coronary artery and arteriorenal blood flow effectively, not only can help the treatment of the heart failure that heart disease caused of a variety of causes, and the coronary artery that heart failure caused, the reduction of renal artery blood flow amount and the damage of renal function are had tangible curative effect.
Two, the present invention is to ischemic heart desease microcirculation and hemorheological influence
1, data and method:
1.1 select to meet coronary heart disease inpatient 63 examples of WHO diagnostic criteria, angina pectoris 34 examples wherein, acute myocardial infarction 29 examples are divided into treatment at random and organize 32 examples, male 17 examples, women 15 examples, matched group 31 examples, male 18 examples, women 13 examples, mean age 49-72 year.
1.2 Therapeutic Method:
The treatment group: add 250-500ml 0.9% normal saline iv drip with injection 25ml of the present invention, every day 1 time, 15 days is a course of treatment.Matched group: add 250-500ml 0.9% normal saline intravenous drip with FUFANG DANSHEN ZHUSHEYE 20ml, every day 1 time, 15 days is a course of treatment.Two groups of conventional therapies of medication viewing duration are constant.
1.3 inspection method: all the person under inspection detects BCM before medication and after finishing the course of treatment, hemorheology index, and BCM detects, record vascular morphology, blood flow state, ambient state integration and total mark, hemorheology detects 200S
-1, 30S
-1, 5S
-1The whole blood viscosity of shear rate, plasma viscosity and erythrocyte aggregation index.
1.4 statistical method: measurement data is represented with X ± S, the t check analysis, and enumeration data is carried out X
2Check.P value＜0.05 is a significant difference.
2, result:
2.1 BCM situation of change before and after two groups of treatments
After treatment group and the treatment of control group with treatment before relatively BCM in various degree improvement is all arranged, improve the most obviously with treatment group blood flow state, ambient state and erythrocyte aggregation degree, integrated value improvement degree treatment group is all remarkable than matched group.See the following form in P＜0.05.
2.2 hemorheology situations before and after two groups of medications: two groups of cases treatment back hemorheologys all take a favorable turn before the treatment, in the whole blood viscosity, lowly cut, the erythrocyte aggregation degree improves obviously, with matched group significant difference P＜0.05 arranged relatively, sees Table 2.
3, discuss: this experimental applications injection of the present invention and compound Salviae Miltiorrhizae are treated 63 routine patients with coronary heart disease, observe injection of the present invention bulbar Conjunctiva Microcirculation BCM and hemorheological improvement obviously are better than compound Salviae Miltiorrhizae, to controlling anginal outbreak and preventing that acute myocardial infarction from all having good curative effect.
Three, the present invention treats the clinical observation of cerebral infarction:
1, clinical data:
1.1 physical data: selected patient's 40 examples, wherein male 24 examples, women 16 examples, age 50-72 year, 57.5 years old mean age.40 routine patients all confirm through cranium brain CT, atheroma cerebral infarction 35 examples wherein, lacunar infarction 5 examples.Selected patient all by the neurologic impairment integration divide equally be divided into light-duty, 0～15 minute, 18 examples; Medium-sized, 16～30 minutes, 12 examples; Heavy 31～45 minutes, 10 examples.
1.2 Therapeutic Method: use capsule of the present invention, take medicine for three times every day, 30 days is a course of treatment, all surveys blood viscosity once before and after the treatment.
1.3 efficacy determination: with the minimizing of neurologic impairment integration, promptly function is improved and the total viability state of patient, and evaluating invalid degree is evaluating basis.Be almost recovered: invalid degree is 0 grade.Produce effects: functional impairment decreases scoring to be reduced more than 21 minutes, and invalid degree has 1～3 grade.Effectively: the functional impairment scoring reduces 8～20 fens.Invalid: the functional impairment scoring reduces below 8 minutes or increases.
2, result: 40 routine patients' therapeutic outcome sees Table 1, table 2.The total effective rate of 40 routine patient treatments reaches 90%, and blood viscosity has in o'clock 40 routine patient's uses of significant difference P＜0.01 untoward reaction does not all take place before and after the treatment.
The observation of curative effect of table 1 40 routine Cerebral Infarction Patients
Contrast before and after the table 2 40 routine blood viscosity X+S treatments
| The low viscosity Gr that cuts of whole blood | |
| Before the treatment | 16.33±3.5 |
| After the treatment | 11.83±4.1 |
| Front and back are poor | 4.50±2.0 |
| The P value | ＜0.01 |
3, discuss: by this experiment 40 routine Cerebral Infarction Patients are used capsule of the present invention and treat on the observation analysis and confirm, capsule of the present invention is remarkable for the ischemic cerebrovascular clinical efficacy, and the brain circular blood stream state of improvement is arranged, lower effects such as blood viscosity, do not see untoward reaction in the therapeutic process, be a kind of safe and effective medicine, be worth in cerebrovascular disease prevention and treatment, wideling popularize.
The specific embodiment:
Embodiments of the invention 1:
Radix Ginseng 80g Radix Astragali 120g Flos Carthami 80g glucose 50g
Get Radix Ginseng, the Milkvetch Root pulverize separately becomes coarse powder, adds the alcohol reflux 3 times of 1600ml 70%, each 2 hours, reclaim ethanol and also be condensed into extractum, Radix Ginseng, Radix Astragali extract.Other gets Flos Carthami, adds the 800ml decocting and boils three times, filters, and merging filtrate adds ethanol precipitate with ethanol twice, contains the alcohol amount and is respectively 65%, 80%.Left standstill 24 hours, and filtered, reclaim ethanol, get Flos Carthami extract.With Radix Ginseng, Radix Astragali extract, Flos Carthami extract and glucose mix homogeneously, add in the 200ml water for injection and dissolve, and continue to add water for injection to 1000ml, transfer PH 7, filter, embedding, promptly get ejection preparation.
Embodiments of the invention 2:
Radix Ginseng 150g Radix Astragali 200g Flos Carthami 120g lactose 300g
Get Radix Ginseng, the Milkvetch Root pulverize separately becomes coarse powder, makes solvent with 65% ethanol, soaks 8 days, carries out percolation, adds the ethanol of 10500ml altogether, merges percolate, reclaims ethanol and also is condensed into extractum, drying promptly gets Radix Ginseng, Radix Astragali extract.Other gets Flos Carthami, adds the 1000ml decocting and boils three times, filters, and filtrate is crossed macroporous adsorptive resins, uses 50% ethanol elution, collects eluent and concentrating under reduced pressure and becomes extractum, gets Flos Carthami extract.With Radix Ginseng, Radix Astragali extract, Flos Carthami extract and lactose mix homogeneously, add in the 200ml water for injection and dissolve, and continue to add water for injection to 1000ml, transfer pH value 2, ultrafiltration, fill, lyophilization promptly gets freeze-dried products.
Embodiments of the invention 3:
Radix Ginseng 300g Flos Carthami 100g PEG400 400g
Preparation technology is: get the ginseng crude drug and be ground into coarse powder, make solvent with 80% ethanol, soaked 15 days, carry out percolation, add 2000ml ethanol altogether, merge percolate, reclaim ethanol and be condensed into extractum, drying promptly gets Radix Ginseng extract.Other gets Flos Carthami powder and is broken into 100 purpose fine powders, with Flos Carthami powder, Radix Ginseng extract mix homogeneously, PEG400 is added mix homogeneously in the above drug powder, splashes in the dimethicone and cools off, and promptly gets drop pill.
Embodiments of the invention 4:
Radix Ginseng 10g Radix Astragali 20g Pulvis Talci 10g
Get Radix Ginseng, be ground into 120 purpose fine powders, get the Radix Ginseng powder.Other gets the Radix Astragali, adds the 200ml decocting respectively and boils three times, and decocting time is respectively 3h, 2h, 1h, filters, merging filtrate, concentrating under reduced pressure becomes extractum, adds ethanol and makes that to contain the alcohol amount be 50%, reclaim ethanol and vacuum concentration and become extractum, lyophilization promptly gets Radix Astragali extract.With Radix Ginseng powder, Radix Astragali extract and Pulvis Talci mix homogeneously, the alcohol granulation with 75%, filling promptly gets capsule.
Embodiments of the invention 5:
Radix Ginseng 2000g, Radix Astragali 5000g, starch 3000g
Get the Radix Astragali, the Radix Ginseng pulverize separately becomes 120 purpose fine powders, is mixed together evenly with starch again, water is granulated, tabletting, reuse 3% film coating agent carries out coating to plain sheet, promptly gets tablet.
Embodiments of the invention 6:
Radix Ginseng 2000g Radix Astragali 3000g Flos Carthami 2000g Oleum Glycines 1300ml
Get Milkvetch Root and be ground into coarse powder, extract with Flos Carthami water decocting method, with ethanol precipitate with ethanol twice, containing the alcohol amount for the first time is 75%, and containing the alcohol amount for the second time is 99%.Reclaim ethanol and be condensed into extractum, drying is ground into 100 purpose fine powders, promptly gets the Radix Astragali, Flos Carthami extract.Get the ginseng crude drug and be ground into coarse powder, use alcohol reflux, reclaim ethanol and be condensed into extractum, drying is ground into 100 purpose fine powders, promptly gets Radix Ginseng extract.Get the Radix Astragali, Flos Carthami extract, Radix Ginseng extract and Oleum Glycines mix homogeneously, pill promptly gets soft capsule.Embodiments of the invention 7:
Radix Ginseng 10g Radix Astragali 10g Flos Carthami 10g sucrose 30g
Get the Radix Astragali, Radix Ginseng, flos carthami pulverizing, water decocts three times, adds 12 times of water gagings for the first time and decocts 3 hours, add for the second time 8 times of water gagings and decocted 2 hours, add 6 times of water gagings for the third time and decocted the leaching decocting liquid 1 hour, merge, concentrating under reduced pressure gets extract, and sucrose is dissolved in the hot water that boils, drop into the said extracted thing, filter, fill promptly gets oral liquid.
Embodiments of the invention 8:
Radix Ginseng 2000g Flos Carthami 5000g sucrose 1500g
Get Flos Carthami, the water decocting method extracts, the leaching decocting liquid, filtrate is carried out the gradient isolated by filtration with the ultrafilter membrane of the sub-very much magnitude of 5-10, discard liquid on the film, the ultrafilter membrane of the sub-very much magnitude of filtrate reuse 0.1-0.3 carries out the gradient isolated by filtration, gets liquid on the thick paste shape film, liquid passes through macroporous resin column under the film, ethanol gradient elution is collected eluent, reclaims ethanol, be concentrated into the thick paste shape, promptly get Flos Carthami extractum.Get the ginseng crude drug and be ground into the above fine powder of 80 orders, promptly get the Radix Ginseng powder.Other gets cane sugar powder and is broken into 100 purpose fine powders.Get Flos Carthami extractum, Radix Ginseng powder and cane sugar powder mix homogeneously and granulation, promptly get granule.
Claims (2)
1. ejection preparation for the treatment of the heart, cerebrovascular disease, it is characterized in that: it be get Radix Ginseng 80g, Radix Astragali 120g pulverize separately becomes coarse powder, adds the alcohol reflux 3 times of 1600ml 70%, each 2 hours, reclaim ethanol and be condensed into extractum, get Radix Ginseng, Radix Astragali extract; Other gets Flos Carthami 80g, adds the 800ml decocting and boils three times, filter, and merging filtrate, adding ethanol precipitate with ethanol twice contains the alcohol amount and is respectively 65%, 80%, leaves standstill 24 hours, filters, and reclaims ethanol, gets Flos Carthami extract; With Radix Ginseng, Radix Astragali extract, Flos Carthami extract and 50g glucose mix homogeneously, add the dissolving of 200ml water for injection, and continue to add water for injection to 1000ml, transfer PH 7, filter embedding, promptly.
2. lyophilized injectable powder for the treatment of the heart, cerebrovascular disease, it is characterized in that: it be get Radix Ginseng 150g, Radix Astragali 200g pulverize separately becomes coarse powder, make solvent with 65% ethanol, soaked 8 days, and carried out percolation, add the ethanol of 10500ml altogether, merge percolate, reclaim ethanol and be condensed into extractum, drying promptly gets Radix Ginseng, Radix Astragali extract; Other gets Flos Carthami 120g, adds the 1000ml decocting and boils three times, filters, and filtrate is crossed macroporous adsorptive resins, uses 50% ethanol elution, collects eluent and concentrating under reduced pressure and becomes extractum, gets Flos Carthami extract; With Radix Ginseng, Radix Astragali extract, Flos Carthami extract and 300g lactose mix homogeneously, add in the 200ml water for injection and dissolve, and continue to add water for injection to 1000ml, transfer pH value 2, ultrafiltration, fill, lyophilization, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100715424A CN100423738C (en) | 2004-07-09 | 2004-07-09 | Chinese medicine preparation for treating cardio-cerebral vascular disease and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100715424A CN100423738C (en) | 2004-07-09 | 2004-07-09 | Chinese medicine preparation for treating cardio-cerebral vascular disease and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1586607A CN1586607A (en) | 2005-03-02 |
| CN100423738C true CN100423738C (en) | 2008-10-08 |
Family
ID=34604605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100715424A Expired - Fee Related CN100423738C (en) | 2004-07-09 | 2004-07-09 | Chinese medicine preparation for treating cardio-cerebral vascular disease and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100423738C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100408052C (en) * | 2005-06-27 | 2008-08-06 | 成都迪康药物研究所 | Medicine composition for treating chronic heart failure and hypotension and its prepn and use |
| CN103690723B (en) * | 2013-09-25 | 2018-06-12 | 王海坡 | A kind of drug for treating apoplexy |
| CN103933268A (en) * | 2014-05-07 | 2014-07-23 | 河南中医学院 | Traditional Chinese medicine composition for controlling body weight and tonifying qi and activating blood circulation and preparation method of traditional Chinese medicine composition |
| CN105267561A (en) * | 2015-11-06 | 2016-01-27 | 王小芬 | Cardiovascular and cerebrovascular disease treatment medicine for oral administration and preparation method of cardiovascular and cerebrovascular disease treatment medicine for oral administration |
| CN114869928B (en) * | 2022-04-27 | 2023-06-06 | 中国人民解放军空军军医大学 | Traditional Chinese medicine composition for treating cerebrovascular disease and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1187996A (en) * | 1997-01-13 | 1998-07-22 | 李国华 | Drug for curing cerebral infarction |
-
2004
- 2004-07-09 CN CNB2004100715424A patent/CN100423738C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1187996A (en) * | 1997-01-13 | 1998-07-22 | 李国华 | Drug for curing cerebral infarction |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1586607A (en) | 2005-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100457176C (en) | Chinese medicinal preparation for curriculum of physical and fatigue reducing | |
| WO2021120972A1 (en) | Traditional chinese medicine composition for treating deficiency of both qi and blood, preparation method therefor and use thereof | |
| CN102772748B (en) | Traditional Chinese medicine preparation for treating liver-depression qi-stagnation type viral myocarditis and preparation method thereof | |
| CN101524469A (en) | Chinese herbal medicine compound preparation for treating congestive heart failure and preparation method thereof | |
| CN100423738C (en) | Chinese medicine preparation for treating cardio-cerebral vascular disease and its preparing method | |
| CN101623437B (en) | Pulse-activating preparation for injection and preparation method thereof | |
| CN1927324A (en) | Preparation method of traditional medicine preparation for treating women's menoxenia | |
| CN102258628A (en) | Chinese medicinal composition with lead removal promoting effect | |
| CN1282464C (en) | Chinese medicinal preparation and preparing method for chronic heart fatilue | |
| CN101322791B (en) | Chinese medicine for treating chronic anemia | |
| CN101940765B (en) | Medicament for treating chronic cerebral circulation insufficiency and preparation method | |
| CN101254266B (en) | Cardiac and cerebral vascular disease treating medicine | |
| CN102988779A (en) | Chinese medicine composition for treating hypertensive nephropathy and preparation method and application of Chinese medicine composition | |
| CN102552861A (en) | Ginseng Sini granules and preparing method thereof | |
| CN101199568A (en) | Medicament compound for treating cardiovascular disease and preparing method thereof | |
| CN101757423B (en) | Traditional Chinese medicine composition for treating myocarditis and preparation method thereof | |
| CN101313989B (en) | Chinese medicinal composition for treating coronary disease, stenocardia | |
| CN1284551C (en) | Chinese medicinal preparation and preparing method for acute cerebral infarction | |
| CN110101800A (en) | It is a kind of to treat malignant pleural effusion Chinese medicine composition and its application | |
| CN101468060A (en) | Pharmaceutical composition | |
| CN103007030B (en) | Preparation method of Chinese medicinal composition and preparation for preventing and treating male infertility | |
| CN102836315A (en) | Chinese medicinal composition for preventing and conditioning prognosis tumors and preparation method thereof | |
| CN100482264C (en) | Shenling Chinese medicine preparation for strengthening body resistance | |
| CN101088530A (en) | Medicine micropill and its prepn process | |
| CN100333771C (en) | Ginseng and astragalis blood glucose loucring dorpping pill, and its preparing and detecting method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081008 |